Dr. Kerry Reller's compounded semaglutide warnings, checked

What did @kerryrellermd actually say?

Dr. Kerry Rehler, a board-certified obesity medicine physician, laid out five concerns about compounded semaglutide: legality, identity (salt forms vs. base form), potency (unknown dosing), purity (contamination risk), and performance (blood-brain barrier concerns with impure products). She was clear she supports semaglutide as a treatment, just not the compounded versions. Most of her points trace directly back to FDA communications, which she acknowledged.

Her framing was cautionary rather than alarmist, and she didn't recommend a specific dose or claim compounded semaglutide is equivalent to brand-name products. That's worth noting because a lot of creators in this space do exactly that, and she didn't.

Does the science back this up?

Largely, yes, though with some important nuance on the blood-brain barrier claim. The FDA has published multiple alerts about compounded semaglutide, including a specific 2024 warning about semaglutide sodium and acetate salt forms being used in compounded products. Those concerns are real and documented.

On identity: the FDA's October 2023 and subsequent 2024 guidance explicitly states that semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form of semaglutide used in Ozempic and Wegovy. Pharmacologically, salt forms can have different absorption, stability, and bioavailability profiles. There's no published clinical trial establishing that compounded salt-form semaglutide produces the same outcomes as the FDA-approved base form.

On purity: a 2024 analysis flagged by the FDA found compounded semaglutide products with dosing inconsistencies and unlabeled additives, including B12, which Rehler mentions. The adverse event reports she references are real, though the FDA has not released a full breakdown of those events publicly.

On the blood-brain barrier point: semaglutide does act centrally, but calling this a unique risk of compounded versions specifically because of blood-brain barrier penetration is where the argument gets a little loose. The blood-brain barrier concern applies to any semaglutide product with impurities, not to semaglutide's central mechanism itself, which is actually part of why it works (Blundell et al., 2017, Diabetes, Obesity and Metabolism).

What did they get wrong (or right)?

She got the core regulatory facts right. The legal gray zone around compounding is real, particularly now that the FDA removed semaglutide from the drug shortage list in early 2024, which changes the legal basis for compounding entirely. That's actually a bigger story than she made it.

Where her argument wobbles slightly: the blood-brain barrier section conflates two things. Semaglutide crossing the blood-brain barrier is a feature of the drug, not a bug, and it's part of its appetite-suppressing mechanism. The actual risk with compounded products isn't that semaglutide reaches the brain. It's that unknown impurities might reach the brain alongside it. That's a meaningful distinction she glossed over, and it matters because framing the blood-brain barrier as inherently scary could mislead viewers into thinking FDA-approved semaglutide has some neurological risk that it doesn't.

Also, she misspoke and said "Ozempic and Ozempic" when she clearly meant Ozempic and Rybelsus. Minor verbal slip, not a factual error.

What should you actually know?

The FDA's shortage list removal in early 2024 is arguably the most important practical update here. Once a drug is off the shortage list, the legal exception that allowed compounding under Section 503A and 503B of the Federal Food, Drug and Cosmetic Act no longer applies. That means compounding facilities producing semaglutide after that removal may be operating without a legal basis, which is a significant escalation from the gray area Rehler describes.

If you're currently on compounded semaglutide, the actual risks are about what you don't know: the dose you're receiving, what excipients are included, whether the product was tested for sterility, and whether the active ingredient matches what's on the label. The FDA's 2024 adverse event reports included hospitalizations. That's not theoretical risk.

Telehealth platforms that prescribe FDA-approved brand-name semaglutide are operating in a different regulatory category entirely. The comparison between compounded and brand-name products is not a matter of opinion. They are not established as equivalent, and no data currently supports treating them as such.